600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fed Conditions

Inclusion Criteria: * Healthy, non-smoking male or non-pregnant, non-lactating female subjects, 18 years of age and over. * Body weight within ±15% of the appropriate weight range published in 1993 by Metropolitan Life Insurance Company, Statistical Bureau and body-mass index (BMI) less than 30. * Negative for: * HIV * Hepatitis B and C * Urine drugs of abuse test (marijuana, amphetamines, barbiturates, cocaine, opiates, benzodiazepines and methadone). * Cotinine (urine test) * Breath alcohol (Breathalyzer) * HCG (females only) * No significant diseases or clinically significant abnormal laboratory values. * No clinically significant findings in the physical examination. * No clinically significant findings in vital sign measurements and 12-lead electrocardiogram (ECG). * Informed of the nature of the study and give written consent prior to receiving any study medication. * Female subjects: surgically steril, post-menopausal or practicing a recognized safe method of contraception (abstention, oral or implanted contraceptives, intra-uterine device or consistent condom plus spermicide use). Exclusion Criteria: * Known history or presence of any disease or condition which might compromise the following body systems: immunologic, endocrine, renal, cardiovascular, respiratory, hematologic, gastrointestinal, neurologic, hepatic, psychiatric or dermatologic * More specifically: history or presence of significant: sensitivity to multiple allergens, diarrhea, stomach or intestinal disease, mononucleosis, renal or hepatic dysfunction and asthma. * Known or suspected carcinoma. * Known history or presence of: * Hypersensitivity or idiosyncratic reaction to amoxicillin, clavulanic acid, penicillin, cephalosporins and/or any other β-lactamase inhibitors. * Clavulin-associated jaundice/hepatic dysfunction. * Alcoholism within last 12 months. * Drug dependence and/or substance abuse. * Use of tobacco or nicotine-containing products, within last 12 months. * On a special diet within 4 weeks prior to drug administration (i.e. a deliberate change in diet for any reason). * Participation in another clinical trial or received an investigational product in the previous 30 days prior to drug administration. * Donation up to 250 mK of blood in the previous 30 days, 251-500 mKL in the previous 45 days, 501-750 mL in the previous 60 days or above 750 mL in the previous 90 days prior to study start. * Requirement of any medication, (prescription and/or over-the-counter) or dietary supplements on a routine basis, with the exception of occasional use of acetaminophen and oral or implanted contraceptives. * Difficulty fasting or consuming the standard prescribed meals.